Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer

• Status: Completed
• Trial end date: 2010-08-01

Summary

Primary evaluation of the safety, tolerability and feasibility regarding specific postoperative complications of an adjuvant treatment with catumaxomab administered after tumor resection.

• Phase: Phase 2

Details

• Lead Sponsor: Neovii Biotech
• Treatments: Antibodies; Antibodies, Bispecific; Catumaxomab; Immunoglobulins